 |
- Conditions: Asthma; Allergic Asthma; Allergies; Healthy
Intervention:
Sponsors: University of Wisconsin, Madison; National Institutes of Health (NIH)
Not yet recruiting - verified July 2017 - Condition: Eosinophilic Esophagitis
Interventions: Drug: APT-1011; Drug: Placebo
Sponsor: Adare Pharmaceuticals, Inc.
Recruiting - verified July 2017 - Conditions: Atopic Dermatitis; Eczema, Atopic
Interventions: Drug: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle; Drug: ALX-101 Gel 5% and ALX-101 Gel Vehicle
Sponsor: Ralexar Therapeutics, Inc.
Recruiting - verified April 2017 - Condition: Atopic Dermatitis
Interventions: Drug: Tralokinumab; Drug: Placebo
Sponsor: LEO Pharma
Recruiting - verified July 2017 - Condition: Atopic Dermatitis
Interventions: Drug: Tralokinumab; Drug: Placebo
Sponsor: LEO Pharma
Recruiting - verified June 2017 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: ribociclib; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: University of Michigan Cancer Center
Recruiting - verified June 2017 - Condition: Asthma
Intervention: Behavioral: Multi-Component Technology Based Intervention
Sponsors: Wayne State University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2017 - Condition: Peanut Allergy
Intervention: Biological: AR101
Sponsor: Aimmune Therapeutics, Inc.
Recruiting - verified July 2017 - Condition: Atopic Dermatitis
Interventions: Drug: INCB018424 cream; Drug: INCB018424 cream; Drug: INCB018424 cream; Drug: Triamcinolone 0.1% cream; Drug: Vehicle cream
Sponsor: Incyte Corporation
Recruiting - verified July 2017 - Conditions: Acute Coronary Syndrome; Chest Pain
Interventions: Procedure: Blood Sample; Behavioral: HEART Score
Sponsors: University of Florida; Roche Diagnostics
Recruiting - verified April 2017 - Conditions: Pruritus; Atopic Dermatitis
Interventions: Drug: Serlopitant High Dose; Drug: Placebo Oral Tablet; Drug: Serlopitant Low Dose
Sponsor: Menlo Therapeutics Inc.
Recruiting - verified May 2017 - Conditions: B Acute Lymphoblastic Leukemia; Bone Necrosis; Central Nervous System Leukemia; Cognitive Side Effects of Cancer Therapy; Neurotoxicity Syndrome; Pain; Ph-Like Acute Lymphoblastic Leukemia; Testicular Leukemia; Therapy-Related Toxicity; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dasatinib; Drug: Dexamethasone; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Hydrocortisone Sodium Succinate; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Pegaspargase; Drug: Prednisone; Radiation: Radiation Therapy; Drug: Thioguanine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting - verified May 2017 - Conditions: Asthma; Healthy
Intervention:
Sponsors: University of Michigan; National Institutes of Health (NIH)
Recruiting - verified August 2016 - Condition: Asthma
Interventions: Drug: Fluticasone furoate; Drug: Placebo; Drug: Montelukast; Drug: Short Acting Beta 2 Agonist
Sponsor: GlaxoSmithKline
Recruiting - verified July 2017 - Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: Chemotherapy; Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Foundation Medicine
Recruiting - verified June 2017 - ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate CancerCondition: Prostatic Neoplasms
Interventions: Drug: BAY1841788 / darolutamide (ODM-201); Drug: Standard ADT (androgen deprivation therapy); Drug: Docetaxel; Drug: Placebo
Sponsors: Bayer; Orion Corporation, Orion Pharma
Recruiting - verified July 2017 - Conditions: Myelodysplastic Syndrome (MDS); Chronic Lymphocytic Leukemia (CLL); Chemotherapy-sensitive Lymphoma; Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma; Acute Myelogenous Leukemia (AML); Acute Biphenotypic Leukemia (ABL); Acute Undifferentiated Leukemia (AUL)
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5; Radiation: Total Body Irradiation (TBI) 200cGy on Day -1; Procedure: Infusion of non-T-cell depleted bone marrow on Day 0; Drug: Busulfan; Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1; Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4; Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1; Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4; Drug: Sirolimus; Drug: Mycophenolate mofetil; Drug: G-CSF; Drug: Pre-HCT Mesna on Days -6 and -5; Drug: Pre-HCT Mesna on Days -2 and -1; Drug: Pre-HCT Mesna on Days -5 and -4; Drug: Post-HCT Mesna
Sponsors: Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation
Recruiting - verified February 2017 - Conditions: Asthma; COPD; Chronic Obstructive Pulmonary Disease
Interventions: Procedure: Blood draw; Procedure: Urine; Procedure: Lung function measurements; Procedure: Fractional Exhaled Nitric Oxide (FENO)
Sponsors: AstraZeneca; Parexel
Recruiting - verified July 2017 - Condition: Eosinophilic Esophagitis (EoE)
Interventions: Drug: Oral Budesonide Suspension (OBS); Drug: Placebo
Sponsor: Shire
Recruiting - verified June 2017 - Condition: Metastatic Hormone Sensitive Prostate Cancer
Interventions: Drug: Enzalutamide; Drug: Placebo
Sponsors: Astellas Pharma Global Development, Inc.; Medivation, Inc.
Recruiting - verified May 2017 - Condition: Heart Failure
Intervention: Other: hsTnT level
Sponsors: Indiana University; Vanderbilt University; Wayne State University; University of Cincinnati
Recruiting - verified October 2016 - Condition: Eosinophilic Esophagitis (EoE)
Interventions: Drug: OBS; Drug: Placebo
Sponsor: Shire
Recruiting - verified June 2017 - Condition: Asthma
Interventions: Drug: QAW039; Drug: QAW039; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2017 - Condition: Asthma
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Inner-City Asthma Consortium
Recruiting - verified August 2016 - Condition: Prostate Cancer
Interventions: Drug: Apalutamide; Drug: Placebo; Drug: Androgen Deprivation Therapy (ADT)
Sponsor: Aragon Pharmaceuticals, Inc.
Recruiting - verified June 2017 - Condition: Rhinitis, Allergic, Seasonal
Interventions: Biological: MK-3641; Biological: Placebo; Drug: Self-injectable epinephrine; Drug: Albuterol/Salbutamol; Drug: Loratadine; Drug: Olopatadine; Drug: Mometasone furoate monohydrate
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified June 2017 - Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Endometrial Undifferentiated Carcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin; Drug: Cediranib Maleate; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Pharmacological Study; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); AstraZeneca
Recruiting - verified June 2017 - Conditions: Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate
Interventions: Drug: Enzalutamide; Drug: Placebo; Drug: Leuprolide
Sponsors: Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified March 2017 - Condition: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Drug: Farletuzumab; Drug: Placebo
Sponsors: Morphotek; Eisai Co., Ltd.
Recruiting - verified February 2017 - Condition: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: Drug: OLAPARIB; Drug: Single agent chemotherapy
Sponsors: AstraZeneca; Myriad Genetic Laboratories, Inc.
Recruiting - verified June 2017 - Condition: Rejection Sensitivity
Intervention:
Sponsors: Stony Brook University; University of Michigan; National Institute of Mental Health (NIMH)
Recruiting - verified September 2016 - Conditions: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Philadelphia Chromosome Positive; Recurrent Adult Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Blinatumomab; Drug: Dasatinib; Other: Laboratory Biomarker Analysis; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Prednisone; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting - verified May 2017 - Condition: Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Interventions: Drug: APR-246; Drug: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Sponsor: Aprea Therapeutics AB
Recruiting - verified July 2017 - Conditions: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: enzalutamide; Drug: bicalutamide; Procedure: orchiectomy; Drug: leuprolide acetate; Drug: goserelin acetate; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2017 - Condition: Obesity
Intervention: Other: Exercise
Sponsors: University of Michigan; American Diabetes Association
Recruiting - verified June 2017 - Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin; Drug: DOXIL; Drug: Dexamethasone; Drug: DOXIL
Sponsors: Janssen Research & Development, LLC; PharmaMar
Recruiting - verified June 2017 - Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Bicalutamide
Sponsors: Southwest Oncology Group; Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI)
Recruiting - verified May 2017 - Condition: Obesity
Intervention:
Sponsors: University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2017
Clinical Trial Locations